Intellia Therapeutics (0JBU) Share Forecast & Price Target

7 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0JBU Analyst Ratings

Moderate Buy

6 Buy

4 Hold

2 Sell

Based on 12 analysts giving stock ratings to

Intellia

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0JBU Stock 12 Month Forecast

Average Price Target

$20.90

▲(59.91% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $20.90 with a high forecast of $49.00 and a low forecast of $9.00. The average price target represents a 59.91% change from the last price of $13.07.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","50":"$50","17.75":"$17.75","28.5":"$28.5","39.25":"$39.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$49.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,17.75,28.5,39.25,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.719,13.663692307692306,16.608384615384615,19.553076923076922,22.49776923076923,25.442461538461536,28.387153846153844,31.33184615384615,34.27653846153846,37.221230769230765,40.16592307692307,43.110615384615386,46.05530769230769,{"y":49,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.719,11.502153846153846,12.285307692307692,13.068461538461538,13.851615384615384,14.63476923076923,15.417923076923076,16.201076923076922,16.98423076923077,17.767384615384614,18.55053846153846,19.333692307692306,20.116846153846154,{"y":20.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.719,10.58676923076923,10.45453846153846,10.322307692307692,10.190076923076923,10.057846153846153,9.925615384615384,9.793384615384616,9.661153846153846,9.528923076923077,9.396692307692307,9.26446153846154,9.13223076923077,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.251,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.379,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.378,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.811,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.748,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.101,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.26,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.118,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.205,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.08,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.719,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$49.00

Average Price Target$20.90

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Debanjana Chatterjee

JonesTrading

$29

Buy

121.88%

Upside

Reiterated

08/14/26

Intellia Therapeutics: Buy Rating Reiterated as Clinical Progress and Risk Management Support Unchanged $29 Price Target

Terence Flynn

Morgan Stanley

$15

Hold

14.77%

Upside

Assigned

08/10/26

Morgan Stanley Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)

Mitchell Kapoor

H.C. Wainwright

$25

Buy

91.28%

Upside

Reiterated

08/07/26

Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA)

Alec Stranahan

Bank of America Securities

$19→$17

Hold

30.07%

Upside

Reiterated

08/07/26

Bank of America Securities Remains a Hold on Intellia Therapeutics (NTLA)

Jonathan Miller

Evercore ISI

$16→$24

Buy

83.63%

Upside

Upgraded

08/07/26

Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISIIntellia Therapeutics upgraded to Outperform from In Line at Evercore ISI

Myles Minter

William Blair

―

Buy

―

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Haemonetics (NYSE: HAE) and Nuvation Bio (NYSE: NUVB)

Whitney Ijem

Canaccord Genuity

$49

Buy

274.90%

Upside

Reiterated

08/06/26

Analyst Maintains Buy on Intellia as Lonvo-z Progress and Strong Cash Runway Support Unchanged $49 Price Target

Salveen Richter

Goldman Sachs

Sell

-31.14%

Downside

Reiterated

08/06/26

Intellia Therapeutics (NTLA) Receives a Sell from Goldman Sachs

Luca Issi

RBC Capital

$15

Hold

14.77%

Upside

Reiterated

08/06/26

RBC Capital Sticks to Its Hold Rating for Intellia Therapeutics (NTLA)

Andy Chen

Wolfe Research

Sell

-31.14%

Downside

Downgraded

07/15/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Intellia Therapeutics (NASDAQ: NTLA)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$12→$17

Hold

30.07%

Upside

Reiterated

07/10/26

Intellia Therapeutics (NTLA) Gets a Hold from Wedbush

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

06/14/26

Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Intellia Therapeutics (NASDAQ: NTLA) and Halozyme (NASDAQ: HALO)

Brian Cheng

J.P. Morgan

Sell

-38.79%

Downside

Reiterated

05/13/26

J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)

William Pickering

Bernstein

$13→$17

Hold

30.07%

Upside

Assigned

05/13/26

Intellia Therapeutics price target raised to $17 from $13 at BernsteinIntellia Therapeutics price target raised to $17 from $13 at Bernstein

Yanan Zhu

Wells Fargo

$15

Hold

14.77%

Upside

Reiterated

05/12/26

Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Debanjana Chatterjee

JonesTrading

$29

Buy

121.88%

Upside

Reiterated

08/14/26

Intellia Therapeutics: Buy Rating Reiterated as Clinical Progress and Risk Management Support Unchanged $29 Price Target

Terence Flynn

Morgan Stanley

$15

Hold

14.77%

Upside

Assigned

08/10/26

Morgan Stanley Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)

Mitchell Kapoor

H.C. Wainwright

$25

Buy

91.28%

Upside

Reiterated

08/07/26

Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA)

Alec Stranahan

Bank of America Securities

$19→$17

Hold

30.07%

Upside

Reiterated

08/07/26

Bank of America Securities Remains a Hold on Intellia Therapeutics (NTLA)

Jonathan Miller

Evercore ISI

$16→$24

Buy

83.63%

Upside

Upgraded

08/07/26

Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISIIntellia Therapeutics upgraded to Outperform from In Line at Evercore ISI

Myles Minter

William Blair

―

Buy

―

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Haemonetics (NYSE: HAE) and Nuvation Bio (NYSE: NUVB)

Whitney Ijem

Canaccord Genuity

$49

Buy

274.90%

Upside

Reiterated

08/06/26

Analyst Maintains Buy on Intellia as Lonvo-z Progress and Strong Cash Runway Support Unchanged $49 Price Target

Salveen Richter

Goldman Sachs

Sell

-31.14%

Downside

Reiterated

08/06/26

Intellia Therapeutics (NTLA) Receives a Sell from Goldman Sachs

Luca Issi

RBC Capital

$15

Hold

14.77%

Upside

Reiterated

08/06/26

RBC Capital Sticks to Its Hold Rating for Intellia Therapeutics (NTLA)

Andy Chen

Wolfe Research

Sell

-31.14%

Downside

Downgraded

07/15/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Intellia Therapeutics (NASDAQ: NTLA)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$12→$17

Hold

30.07%

Upside

Reiterated

07/10/26

Intellia Therapeutics (NTLA) Gets a Hold from Wedbush

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

06/14/26

Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Intellia Therapeutics (NASDAQ: NTLA) and Halozyme (NASDAQ: HALO)

Brian Cheng

J.P. Morgan

Sell

-38.79%

Downside

Reiterated

05/13/26

J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)

William Pickering

Bernstein

$13→$17

Hold

30.07%

Upside

Assigned

05/13/26

Intellia Therapeutics price target raised to $17 from $13 at BernsteinIntellia Therapeutics price target raised to $17 from $13 at Bernstein

Yanan Zhu

Wells Fargo

$15

Hold

14.77%

Upside

Reiterated

05/12/26

Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Intellia Therapeutics

3 Months

Mani ForooharLeerink Partners

Success Rate

14/39 ratings generated profit

Average Return

+4.67%

Copying Mani Foroohar's trades and holding each position for 3 Months would result in 35.90% of your transactions generating a profit, with an average return of +4.67% per trade.

1 Year

Joseph ThomeTD Cowen

Success Rate

7/18 ratings generated profit

Average Return

-15.66%

Copying Joseph Thome's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of -15.66% per trade.

2 Years

Joseph ThomeTD Cowen

Success Rate

6/18 ratings generated profit

Average Return

-20.24%

Copying Joseph Thome's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -20.24% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0JBU Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0JBU has received 9 Buy Ratings, 7 Hold Ratings, and 3 Sell Ratings. 0JBU average Analyst price target in the past 3 months is 20.90.

Each month's total comprises the sum of three months' worth of ratings.

0JBU Financial Forecast

0JBU Earnings Forecast

Next quarter’s earnings estimate for 0JBU is -$0.80 with a range of -$0.89 to -$0.72. The previous quarter’s EPS was -$0.80. 0JBU beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0JBU has Performed in-line its overall industry.

0JBU Sales Forecast

Next quarter’s sales forecast for 0JBU is $10.23M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $7.66M. 0JBU beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0JBU has Performed in-line its overall industry.

0JBU Stock Forecast FAQ

What is GB:0JBU’s average 12-month price target, according to analysts?

Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is 20.90.

What is GB:0JBU’s upside potential, based on the analysts’ average price target?

Intellia Therapeutics has 59.91% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Intellia Therapeutics a Buy, Sell or Hold?

Intellia Therapeutics has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 4 hold ratings and 2 sell ratings.

What is Intellia Therapeutics’s share price target?

The average share price target for Intellia Therapeutics is 20.90. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $49.00 ,and the lowest forecast is $9.00. The average share price target represents 59.91% Increase from the current price of $13.07.

What do analysts say about Intellia Therapeutics?

Intellia Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Intellia Therapeutics?

To buy shares of GB:0JBU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Intellia Therapeutics (0JBU) Share Forecast & Price Target

0JBU Analyst Ratings

0JBU Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Intellia Therapeutics

0JBU Analyst Recommendation Trends

0JBU Financial Forecast

0JBU Earnings Forecast

0JBU Sales Forecast

0JBU Stock Forecast FAQ

Detailed List of Analyst Forecasts